8-K: Ocuphire Pharma Acquires Opus Genetics, Creating Gene Therapy Leader for Inherited Retinal Diseases

Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, forming a leading clinical-stage company focused on gene therapy treatments for rare inherited retinal degenerations.

Summary

• Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, creating a company focused on developing gene therapies for inherited retinal diseases (IRDs).
• The combined company will be renamed Opus Genetics, Inc., effective October 23, 2024, and will trade on Nasdaq under the ticker symbol IRD effective October 24, 2024.
• The merger brings together Ocuphire's late-stage ophthalmic drug development expertise with Opus Genetics' gene therapy pipeline.
• The combined company has a pro forma cash balance of approximately $37 million as of September 30, 2024, with an expected cash runway into 2026.
• The company will seek a strategic partner for its APX3330 program for diabetic retinopathy and redirect resources to the gene therapy programs.
• The lead gene therapy candidate, OPGx-LCA5, has shown visual improvement in all three adult patients in a Phase 1/2 trial at 6 months.
• Enrollment of pediatric patients in the OPGx-LCA5 Phase 1/2 trial is expected in Q1 2025, with initial data anticipated in Q3 2025.
• The company anticipates clinical data readouts for OPGx-BEST1 in Q4 2025.
• Top-line data from the LYNX-2 Phase 3 trial for dim light disturbances is expected in Q1 2025, and top-line data from the VEGA-3 Phase 3 trial for presbyopia is expected in the first half of 2025.
• Ocuphire issued 5.2 million shares of common stock and 14.1 thousand shares of convertible preferred stock to Opus Genetics stockholders.

Sentiment

Score: 8

Explanation: The document is highly positive, highlighting a strategic acquisition, promising clinical data, and a strong financial outlook. The focus on gene therapy for rare diseases and the potential for multiple near-term milestones contribute to a favorable sentiment.

Positives

• The acquisition combines Ocuphire's late-stage development expertise with Opus Genetics' gene therapy pipeline.
• The combined company has a strong cash position with a runway into 2026.
• OPGx-LCA5 has shown promising early clinical data with visual improvement in all three adult patients.
• The company has multiple near-term clinical milestones expected in 2025.
• The company has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA for OPGx-LCA5.

Negatives

• The company will seek a strategic partner for its APX3330 program, indicating a shift in focus and potential delay in that program's development.
• The company is dependent on the success of clinical trials and regulatory approvals for its gene therapy programs.

Risks

• The success of clinical trials and regulatory approvals for the gene therapy programs is uncertain.
• The company may face challenges in integrating the two companies and their respective pipelines.
• The company is dependent on securing a strategic partner for the APX3330 program.
• The company may face competition from other companies developing gene therapies for inherited retinal diseases.
• The company may require additional capital in the future to fund its operations.

Future Outlook

The combined company anticipates clinical data readouts for multiple programs in 2025 and will seek a strategic partner for the APX3330 program. The company expects to continue to advance its gene therapy pipeline and bring transformative treatments to patients with inherited retinal diseases.

Management Comments

• George Magrath, M.D., stated that the acquisition is an opportunity to advance treatments quickly, with four major clinical milestones on the horizon in 2025.
• Ben Yerxa, Ph.D., believes the combined company is well-positioned to accelerate its pipeline of gene therapies for inherited retinal diseases.
• Jean Bennett, M.D., Ph.D., commented that the efficacy data in patients with late-stage disease is exciting and supportive of the potential for a one-time treatment with OPGx-LCA5.

Industry Context

This announcement reflects the growing interest and investment in gene therapy for rare diseases, particularly in ophthalmology. The acquisition positions the combined company as a significant player in the development of treatments for inherited retinal diseases, a field with high unmet medical need.

Comparison to Industry Standards

• The company's lead gene therapy candidate, OPGx-LCA5, is being developed using AAV vector technology, similar to Luxturna, a commercially available gene therapy for a different form of inherited retinal disease.
• The company's approach to gene therapy development is consistent with industry standards, focusing on well-studied AAV vectors and established regulatory pathways.
• The company's focus on rare diseases aligns with the trend of pharmaceutical companies developing treatments for niche patient populations with high unmet medical needs.
• The company's clinical trial design for OPGx-LCA5, which includes a dose-escalation study, is a common approach in early-stage gene therapy development.
• The company's plan to seek a strategic partner for its APX3330 program is a common strategy for companies with multiple assets in development, allowing them to focus resources on their core programs.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Ocuphire and Opus will have their ownership stakes adjusted based on the merger agreement.
• Employees of both companies will be integrated into the new organization.
• Patients with inherited retinal diseases may benefit from the accelerated development of gene therapies.
• Customers of Ocuphire's existing products may see changes in the company's focus and resources.

Next Steps

• Enrollment of pediatric patients in the OPGx-LCA5 Phase 1/2 trial is expected in Q1 2025.
• Initiation of the OPGx-BEST1 Phase 1/2 clinical trial in Germany is planned.
• The company will seek a strategic partner for the APX3330 program.
• Top-line data from the LYNX-2 Phase 3 trial is expected in Q1 2025.
• Top-line data from the VEGA-3 Phase 3 trial is expected in the first half of 2025.

Key Dates

Keywords

gene therapy, inherited retinal diseases, OPGx-LCA5, OPGx-BEST1, Phentolamine Ophthalmic Solution, APX3330, clinical trials, biopharmaceutical, ophthalmology, merger, acquisition